Vertex’s ‘Slow Train To Pain’ R&D Rolls On
VX-548 Moves To Phase II
Vertex is advancing its sodium channel inhibitor VX-548 to mid-stage trials in the second half of the year as a potential treatment for pain after bunionectomy and abdominoplasty procedures.
